![]() Frequency of the most common manifestations of local injection-site reactions, by dose, were swelling (18% and 15%), erythema (18% and 20%), and pain (24% and 18%). Local injection-site reactions occurred after 24% and 25% of first and second doses, respectively. It’s also possible you might experience peeling, cracks, sores, or rashes. Delayed large local reactions occurred after 15% of first doses and after 18% of second doses. Chemotherapy can cause side effects for your skin, including dryness, redness, and irritation. The Pfizer subgroup represented a smaller sample size (34 first-dose reports and 40 second-dose reports), but the pattern of skin reactions was similar to that observed with the Moderna vaccine. No other type of reaction occurred in more than 1%-2% of patients after either dose. Erythromelalgia occurred after 5.9% of second doses, and cosmetic filler reactions occurred after 4.9% of second doses. Measles-like morbilliform rash occurred after the first dose of Moderna vaccine in 4.1% of patients and after the second dose in 6.9%. An additional 2% of patients developed urticaria within the first 24 hours (all after the second dose). In most cases, the rash arose more than 24 hours after dosing (4.8% after the first dose, 4.9% after the second). Urticaria was the next most common type of skin reaction associated with the Moderna vaccine. Registry participants collected information on the type and timing of vaccine doses and the morphology, timing, duration, and treatment of reactions. You can expect some redness, irritation and a stinging sensation, as well as flaking, as your skin begins to exfoliate. ![]() ![]() "Understandably, the clinical trials were focused on their major endpoints and didn't really provide a lot of detail on the skin reactions seen in patients."Įstablished in March 2020 to accumulate information on cutaneous manifestations of COVID-19, the registry expanded in December to include vaccine-related skin reactions, shortly after the FDA issued the first emergency use authorizations (EUAs) for the vaccines. "We have been involved with following skin reactions to COVID-19 vaccines, but the paper is pretty novel in that it covers a whole range of reactions that had not been reported from vaccine clinical trials," registry principal investigator Esther Freeman, MD, PhD, of Massachusetts General Hospital in Boston, told MedPage Today. They were discussed during the recent AAD virtual meeting and published simultaneously in the Journal of the American Academy of Dermatology. The findings came from the COVID-19 Dermatology Registry, a joint effort of the American Academy of Dermatology (AAD) and the International League of Dermatologic Societies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |